Research on the drugs used to treat cancer and how well they work. Covers immunotherapy, chemotherapy-free regimens, biosimilars, targeted drugs, and treatment costs.
Researchers found that combining pan-Bcl-2 inhibitors with cancer treatments can cause healthy cells to die, leading to reproductive and developmental defects. The study highlights the need for awareness about adverse effects of certain drugs like navitoclax.
Researchers identified phosphoprotein biomarkers to guide cancer therapy, demonstrating a novel approach for identifying and detecting tumor drivers. The study's findings suggest that precision medicine is a realizable goal for rare and recalcitrant cancers.
A deep learning algorithm can quickly and accurately screen cancer patient biopsies for genetic alterations that inform treatment options and likelihood to respond to specific therapies. The study found detectable mutations in 13 out of 14 tested tumor types, including lung, colorectal, breast, and gastric cancers.
Researchers found that patients treated with radioactive iodine and surgery for hyperthyroidism have a higher risk of dying from solid cancer compared to those treated with anti-thyroid drugs. The study suggests that the long-term effects of these treatments on cancer mortality rates are significant.
Physician-scientists use a comprehensive genomic analysis tool to determine the best treatment plan for each individual patient. The study suggests that mutations in the TERT gene can predict a patient's response to immune checkpoint inhibitors.
Newly released CCC19 data show a racial disparity in access to Remdesivir, an antiviral drug that shortens hospital stays, and increased mortality associated with dexamethasone, a steroid. Black patients were half as likely to receive Remdesivir as white patients.
Researchers found that some mutations actually generate 'noise' that can counteract cancer development, leading to a dead end. New drug combinations aim to reactivate suppressed pathways to disrupt oncogenic signal transduction in cancer cells.
Researchers have demonstrated the potential of a leukemia drug, arsenic trioxide, to treat medulloblastoma, a type of brain cancer most common in children. The drug made tumor cells more sensitive to radiation therapy and proved capable of killing tumor cells and preventing new colony formation.
Scientists have tracked quadruple helix DNA formation in living human cells for the first time, allowing them to see how it works and its possible role in cancer. The discovery could reveal new targets for drugs that interrupt gene expression, a fundamental process in gene regulation.
Scientists have discovered a potential new target for treating Ewing sarcoma, a childhood cancer that affects the bone and soft tissue. The researchers found that an imbalance in genetic code-reading machines causes nucleoli to break up into smaller entities in Ewing sarcoma.
Researchers discovered that a protein called Neuropilin-1 (NRP1) suppresses immune responses to cancer. Blocking NRP1 improves the immune system's ability to remember tumors, leading to better protection against recurrence and improved response to immunotherapy.
Researchers at Uppsala University have discovered new ways to combine drugs for glioblastoma patients, tailoring therapy to individual tumours. The study characterised how genetic aberrations influence drug effectiveness, revealing two main subgroups based on response and mutations.
Moffitt researchers found that umbralisib, a PI3K/CK1ε inhibitor, showed fewer immune-mediated side effects compared to traditional PI3K inhibitors. The study suggests that dual inhibition may improve safety profiles for CLL patients.
Researchers found that arsenic trioxide can restore the body's natural antiviral factories to fight adenovirus infections. The medication has been approved for leukemia treatment and shows promise in inhibiting adenovirus replication without developing resistance.
Peter S. Conti, MD, PhD, received the 2020 Benedict Cassen Prize for his pioneering work in radiopharmaceuticals and clinical PET applications for cancer imaging. The award recognizes his contributions to advancing nuclear medicine and molecular imaging.
A study by TGen has identified a drug, SP-2577, which can enable the immune system to attack ovarian cancer. The drug, also known as Seclidemstat, was developed to inhibit LSD1, a protein that is abundant in SCCOHT ovarian cancer.
A ground-breaking clinical trial is underway at Sheba Medical Center in Israel to evaluate the Immunicom LW-02 plasma filtration device as a monotherapy and in combination with an anti-PD-1 immune checkpoint inhibitor. The trial aims to treat resistant metastatic melanoma, triple-negative breast cancer, renal cell carcinoma, and non-sm...
A recent study analyzing 10 years of HPV-vaccine related Facebook posts reveals that anti-vaxxers have gained a stronger voice against the use of the human papillomavirus vaccine. Negative posts displayed a 45% increase in public engagement, with some showing negative views on vaccine safety and effectiveness.
A large study found that taking common hypertension medications such as ACE inhibitors and ARBs can lower the risk of developing colorectal cancer. The benefits were seen in patients over 55 and those with a history of colon polyps, but only for the first three years after a negative baseline colonoscopy.
A study published in CANCER found that Medicaid expansion significantly reduced the likelihood of being diagnosed with deadly metastatic cancer among Americans with low income. The research analyzed data from 12,760 individuals and showed a 15% lower odds of having metastatic cancer after Medicaid expansion.
Brooke Emerling receives a four-year grant to study targeting tumors with p53 gene mutations, which are present in most human cancers. Her research aims to develop new approaches to eliminating cancer as a major health problem.
Researchers found that a low-dose combination of four inhibitors is more effective in treating NSCLC with EGFR mutation. The therapy, called MLD, inhibits the action of multiple proteins in the same signaling pathway, blocking cell proliferation and tumor growth.
Researchers found that olaparib depletes the store of immature eggs in mouse ovaries by 36%, potentially affecting a woman's fertility. Fertility preservation counselling should be considered for young female patients prior to olaparib treatment.
Researchers found that a single change in the GRP94 protein causes it to behave abnormally, leading to widespread dysfunction in cells. A new small molecule PU-WS13 has been identified as a potential treatment for cancer and Alzheimer's disease by repairing defects in the defective protein.
Researchers have discovered a novel protein, death-associated protein 3 (DAP3), that drives the growth of cancers by altering genetic code. DAP3 inhibits RNA editing, which normally corrects genetic errors, acting as an oncogene and promoting cancer development.
A Yale Cancer Center study confirms the effectiveness of combining chemotherapy and trastuzumab in treating aggressive uterine serous carcinoma, a rare form of endometrial cancer. The treatment significantly improves progression-free survival, with no increase in toxicity.
A new study suggests that a type of MRI scan used for heart disease can also pick out aggressive cancers in children. The T1-mapping technique measures how water molecules interact inside cells, allowing clinicians to understand the cellular make-up of tissue and spot early signs of treatment effectiveness.
Russian scientists have discovered four new steroid substances extracted from starfish that target human breast cancer and colorectal carcinoma cells. These non-typical derivatives of polar steroids may also help nerve cells survive distress, suggesting potential applications in Alzheimer's disease prevention.
A new study has identified a key signaling pathway in the development of Paget's disease, a rare and debilitating skin cancer. Researchers found that using a topical cream containing an FDA-approved drug can alleviate clinical symptoms in patients with Paget's disease.
A new study reveals that the enzyme SAMHD1 protects B-ALL cells from nelarabine's anti-cancer effects, but not T-ALL cells. This discovery has crucial implications for leukaemia treatment, offering a potential biomarker to tailor therapy to individual patient needs.
A new study from Memorial Sloan Kettering Cancer Center finds that increased activity of the normal metabolic enzyme SHMT2 transforms normal B cells into B cell lymphomas. The enzyme binds to tumor suppressor proteins, turning them off and resulting in the development of lymphoma.
A new study finds that chemicals can cause changes in cells to evade the immune system and build resistance to cancer drugs. The team identified specific combinations of mutations that create cancer cells, which could aid doctors in prescribing the most appropriate course of chemotherapy.
Researchers at Goethe University Frankfurt and University of Kent have discovered that the enzyme SAMHD1 can split phosphate groups off nelarabine, making it less effective in B-ALL patients. This breakthrough could lead to more targeted treatment options for individual patients.
A new study finds that high deductible health plans are widening the racial health gap among black and white cancer survivors. Black cancer survivors on these plans face significant cost-related barriers to care, including skipping medication or delaying refills.
A study by Queen Mary University of London uncovers novel pathways controlling cancer progression, identifying Rac1 as a critical player in MET-driven processes. The findings may pave the way for more efficacious treatment regimens by targeting MET, PI3K, and mTOR.
Researchers at UC San Diego School of Medicine discovered a new way to treat cancer by manipulating macrophages, immune cells found in tumor tissues. IRE1α, a molecule regulating the unfolded protein response, was shown to boost PD-L1 levels on macrophages, allowing tumors to evade the immune system.
A recent study by SWOG Cancer Research Network found that black cancer patients are more likely to be enrolled in taxpayer-funded clinical trials compared to industry-sponsored trials. The study analyzed data from over 93,000 patients across 358 trials and found a significant disparity in representation.
Scientists at City of Hope and TGen found that circulating immune cell dynamics can inform how patients respond to immunotherapy. The study's findings highlight an important predator-prey relationship between immune cells and tumor response.
A large retrospective cohort study found that flu vaccination was associated with a small increased risk for subdeltoid bursitis. Researchers suggest education and training on proper injection technique could prevent this adverse event.
A new class of precision medicine targeting cancer's ability to repair its DNA has shown promising results, with half of patients experiencing tumor growth halt. The drug works by stopping cancers from repairing DNA damage and is particularly effective when combined with chemotherapy.
Researchers at the University of South Australia have developed a novel formulation of the prostate cancer drug abiraterone acetate, improving its effectiveness by 40%. The new oral formulation reduces side effects and allows for a smaller dose to be effective without fasting.
KinaRx aims to create more effective drugs using a novel platform that targets gene mutations driving cancer growth. The company has developed novel RET inhibitors with promising results in preclinical experiments.
Researchers have found that certain cancer therapeutics concentrate within cells' tiny functional compartments called organelles, known as condensates. This discovery could lead to a new toolset for drug development by tailoring chemicals to seek out and concentrate in specific droplets.
A 84-year-old woman with breast cancer and controlled hypertension developed a life-threatening arrhythmia after chloroquine treatment, resolving after discontinuation. The case highlights the risks of QT interval prolongation and torsade de pointes in patients treated with chloroquine for COVID-19.
A cancer drug called ruxolitinib was used to treat a COVID-19 patient with acute respiratory distress, resulting in clinical stabilization and rapid improvement in respiration and heart function. The treatment's success has led to the approval of a clinical trial to test its effect on additional COVID-19 patients.
A new study has discovered a direct link between mutations in the p53 tumor suppressor gene and the KRAS oncogene, driving the formation of pancreatic cancer. The research provides insight into the mechanism that regulates cell activity, offering potential therapeutic targets for future development.
A new study by American Cancer Society finds that cancer survivors experiencing higher medical and nonmedical financial hardships are more likely to visit the emergency department, receive less preventive care, and have worse self-rated health. The study highlights the growing healthcare costs and their impact on worsening health dispa...
Researchers developed a new test, PrOTYPE, to classify high-grade serous ovarian cancer into four molecular subtypes. This test allows clinicians to tailor treatments to individual patients' tumours with over 95% accuracy.
Researchers developed a new method, HT-DBP, to screen thousands of drugs in freshly collected human tumor cells, potentially leading to more accurate and personalized treatment. The technique indicates which drugs are most likely to be effective against specific cancers, improving physicians' ability to tailor treatment.
In a phase 2 trial, berzosertib, an ATR protein inhibitor, was found to significantly extend progression-free survival for patients with ovarian cancer compared to chemotherapy alone. The drug targets a protein crucial for cancer cell growth and division.
City of Hope scientists have developed two potent small molecules, CS1 and CS2, which inhibit the FTO protein and suppress tumor growth in various cancers. The compounds demonstrate significant anti-tumor effects and improved overall survival in mice with acute myeloid leukemia and breast cancer.
Ashion Analytics has been certified for the National Cancer Institute's MATCH program, offering a comprehensive genomic analysis of all possible cancer mutations in DNA and RNA. This allows for personalized treatment options and potentially life-changing outcomes.
The COVID-19 pandemic is worsening existing drug shortages in the US, particularly for cancer treatments and critical care medications. Experts recommend improved communication and sharing mechanisms among hospitals and healthcare providers to address these shortages.
Researchers create sugar-tagged drug compounds to target chemotherapy-resistant prostate cancer cells, exploiting the Warburg effect. The new compound shows improved efficiency in killing cancer cells compared to traditional chemotherapeutic drugs.
Researchers at Yale University have made a breakthrough in treating Rett Syndrome, a devastating genetic disorder affecting 1 in 10,000 girls. The experimental cancer drug JQ1 has been shown to extend the life of mice with Rett Syndrome by approximately 50%.
Researchers at NUI Galway have discovered a key role for CDC7 in cancer cell replication, providing new insights into developing novel treatments. The study found that blocking CDC7 could be an effective strategy for treating aggressive cancers like pancreatic and colon cancer.
Researchers have identified a new strategy to tackle cancer by inducing toxic autophagy in tumor cells, resulting in cell destruction. The antitumor drug ABTL0812 has been shown to manipulate dihydroceramides, a group of cellular lipids, causing stress and ultimately leading to cancer cell death.
Oncology pharmacy practitioners worldwide are struggling with limited and restricted PPE supply, making it difficult for them to provide high-quality cancer care. In a study, half of the surveyed countries reported impaired access to essential medications, including anti-infective agents and anticancer medications.
A new study found that cancer cells adapt by gobbling up fat molecules from their environment when they can't make their own, potentially rendering treatments ineffective. The research identified a new gene, LUR1, involved in lipid uptake and suggests targeting this process could lead to more effective cancer treatments.
Researchers have identified a variant in the genome associated with higher risk of prostate cancer in African American men. This variant is found in about 12% of men of African ancestry and increases their risk two-fold.